Artrosilene, 1 piece, 25 ml, 15%, aerosol for external use

Artrosilene, 1 piece, 25 ml, 15%, aerosol for external use

Capsules

Suction.

When administered orally, ketoprofen is quite completely absorbed from the gastrointestinal tract, and its bioavailability exceeds 80%. Cmax in plasma when taking Artrosilene capsules is observed 4–10 hours after oral administration, its value directly depends on the dose taken and is 3–9 μg/ml. T1/2 is 6.5 hours. The maximum therapeutic effect is observed over a period of 4 to 24 hours. Food helps to reduce Cmax values ​​​​and increase Tmax without changing AUC.

Distribution.

Up to 99% of absorbed ketoprofen is bound to plasma proteins, mainly albumin. Vd - 0.1–0.2 l/kg. Easily penetrates histohematic barriers and is distributed in tissues and organs. Ketoprofen penetrates well into synovial fluid and connective tissue. Although the concentration of ketoprofen in synovial fluid is slightly lower than in plasma, it is more stable (lasts up to 30 hours).

Metabolism.

Ketoprofen is primarily metabolized in the liver, where it undergoes glucuronidation to form esters with glucuronic acid.

Excretion.

Metabolites are excreted in the urine. Less than 1% is excreted in feces. The drug does not accumulate.

Solution for intravenous and intramuscular administration

Tmax for parenteral administration is 20–30 minutes. The effective concentration lasts 24 hours. Therapeutic concentration in synovial fluid lasts 18–20 hours.

Distribution.

Up to 99% of absorbed ketoprofen is bound to plasma proteins, mainly albumin. Vd - 0.1–0.2 l/kg. Easily penetrates histohematic barriers and is distributed in tissues and organs. Ketoprofen penetrates well into synovial fluid and connective tissue. Although the concentration of ketoprofen in synovial fluid is slightly lower than in plasma, it is more stable (lasts up to 30 hours).

Metabolized by microsomal liver enzymes. Excreted by the kidneys, 60–80% in the form of glucuronide in 24 hours.

Suppositories

Suction.

Ketoprofen lysine salt is rapidly absorbed: Tmax after rectal administration is 45–60 minutes. The plasma concentration depends linearly on the dose taken.

Distribution.

Up to 99% of absorbed ketoprofen is bound to plasma proteins, mainly albumin. Vd - 0.1–0.2 l/kg. Easily penetrates histohematic barriers and is distributed in tissues and organs. Ketoprofen penetrates well into synovial fluid and connective tissue. Although the concentration of ketoprofen in synovial fluid is slightly lower than in plasma, it is more stable (lasts up to 30 hours).

Metabolism.

Ketoprofen is primarily metabolized in the liver, where it undergoes glucuronidation to form esters with glucuronic acid.

Excretion.

Metabolites are excreted mainly in the urine (up to 76% after 24 hours). The drug does not accumulate.

Gel, aerosol

When applied cutaneously, it is absorbed slowly; a dose of 50–150 mg over 5–8 hours produces a plasma concentration level of 0.08–0.15 mcg/ml. Practically does not accumulate in the body. Bioavailability is about 5%.

Nosological classification (ICD-10)

• L40.5 Arthropathic psoriasis (M07.0-M07.3*, M09.0*)
• M06.9 Rheumatoid arthritis, unspecified
• M10 Gout
• M35 Other systemic connective tissue disorders
• M42 Osteochondrosis of the spine
• M45 Ankylosing spondylitis
• M65 Synovitis and tenosynovitis
• M71 Other bursopathies
• M77.9 Enthesopathy, unspecified
• M79.0 Rheumatism, unspecified
• M79.1 Myalgia
• M79.9 Soft tissue disease, unspecified
• R52.0 Acute pain
• R52.2 Other persistent pain
• T14.9 Injury, unspecified
• Z100* CLASS XXII Surgical practice

Side effects

Capsules, solution for intravenous and intramuscular administration, suppositories

From the gastrointestinal tract: abdominal pain, diarrhea, stomatitis, esophagitis, gastritis, duodenitis, erosive and ulcerative lesions of the gastrointestinal tract, hematomesis, melena.

From the liver: increased bilirubin levels, increased activity of liver enzymes, hepatitis, liver failure, increased liver size

From the nervous system: dizziness, hyperkinesia, tremor, vertigo, mood swings, anxiety, hallucinations, irritability, general malaise.

From the senses: conjunctivitis, visual impairment.

From the skin: urticaria, angioedema, erythematous exanthema, itching, maculopapular exanthema, increased sweating, exudative erythema multiforme (including Stevens-Johnson syndrome).

From the genitourinary system: painful urination, cystitis, edema, hematuria, menstrual irregularities.

From the hematopoietic organs: leukocytopenia, leukocytosis, lymphangitis, decreased PV, thrombocytopenia, thrombocytopenic purpura, enlarged spleen, vasculitis.

From the respiratory system: bronchospasm, dyspnea, sensation of laryngeal spasm, laryngospasm, laryngeal edema, rhinitis.

From the cardiovascular system: hypertension, hypotension, tachycardia, chest pain, syncope, peripheral edema, pallor.

Allergic reactions: anaphylactoid reactions, swelling of the oral mucosa, pharyngeal edema, periorbital edema.

Suppositories additionally

Local reactions: burning, itching, heaviness in the anorectal area, exacerbation of hemorrhoids.

Gel, aerosol

Allergic reactions, photosensitivity.

If any adverse event occurs, you should consult a doctor.

Use during pregnancy and breastfeeding

Capsules, solution for intravenous and intramuscular administration, suppositories

Like other NSAIDs, Artrosilene should not be used in the third trimester of pregnancy. The use of the drug in the first and second trimesters should be carefully monitored by the attending physician. Breastfeeding should be discontinued while using the drug.

Gel, aerosol

Cannot be used in the third trimester of pregnancy.

There is no experience with the use of Artrosilene during lactation. Use in the first and second trimesters is possible only after consultation with a doctor.

Composition and release form

10 pcs in blister; 1 blister in a cardboard pack.

in dark glass ampoules of 2 ml; 6 pcs in a pallet, 1 pallet in a cardboard pack.

5 pcs per strip; 2 strips in a cardboard pack.

in aluminum tubes of 30 and 50 g; in a cardboard pack 1 tube.

in 25 ml cylinders with a spray nozzle; 1 cylinder in a cardboard pack.

Pharmacodynamics

It has anti-inflammatory, analgesic and antipyretic effects. By inhibiting COX-1 and -2, it inhibits the synthesis of PG. It has anti-bradykinin activity, stabilizes lysosomal membranes and delays the release of enzymes from them that contribute to tissue destruction during chronic inflammation. Reduces the release of cytokines, inhibits the activity of neutrophils.

Reduces morning stiffness and swelling of joints, increases range of motion.

Ketoprofen lysine salt, unlike ketoprofen, is a rapidly soluble molecule with a neutral pH and is almost non-irritating to the gastrointestinal tract.

When applied topically, it has local anti-inflammatory, antiexudative and analgesic effects. In the form of a spray or gel, it provides a local therapeutic effect on affected joints, tendons, ligaments, and muscles. In case of articular syndrome, it causes a decrease in joint pain at rest and during movement, a decrease in morning stiffness and swelling of the joints. The lysine salt of ketoprofen does not have a catabolic effect on articular cartilage.

Interaction

Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, flumecinol, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites.

Reduces the effectiveness of uricosuric drugs, enhances the effect of anticoagulants, antiplatelet agents, fibrinolytics, ethanol, side effects of mineralocorticoids, corticosteroids, estrogens; antihypertensive and diuretic drugs.

Combined use with other NSAIDs, corticosteroids, ethanol, corticotropin can lead to the formation of ulcers and the development of gastrointestinal bleeding, increasing the risk of developing renal dysfunction.

Co-administration with oral anticoagulants, heparin, thrombolytics, antiplatelet agents, cefoperazone, cefamandole and cefotetan increases the risk of bleeding.

Increases the hypoglycemic effect of insulin and oral hypoglycemic drugs (dose recalculation is necessary).

Co-administration with sodium valproate causes disruption of platelet aggregation.

Increases plasma concentrations of verapamil and nifedipine, lithium, methotrexate.

Antacids and cholestyramine reduce absorption.

Description of the dosage form

Capsules: oblong hard gelatin capsules; the body is white, the lid is dark green. The contents of the capsule are round granules from white to light yellow.

Solution for intravenous and intramuscular administration: transparent, colorless or slightly yellowish solution.

Rectal suppositories: homogeneous, from white to light yellow, torpedo-shaped.

Gel: transparent, thick, with the smell of lavender.

Aerosol: white homogeneous foam; after the gas escapes, it is a clear, pale yellow liquid.

Directions for use and doses

Inside, parenterally, rectally, externally.

The drug is prescribed 1 caps orally. per day during or after meals. The duration of treatment can be 3–4 months.

IM or IV 1 amp. per day. The maximum daily dose is 1 amp. 2 times a day. IV administration of the drug is allowed only in a hospital. The drug is used for short-term treatment - up to 3 days. If further use of the drug is necessary, it is recommended to switch to oral dosage forms or suppositories. In elderly patients, use no more than 1 amp. per day.

Ampoules should be opened along a special break line. After opening the ampoule, use the solution immediately.

Aqueous solutions of ketoprofen lysine salt can be used in physiotherapeutic treatment (iontophoresis, mesotherapy); In iontophoresis, the solution is applied to the negative pole.

When administered intravenously, a slow intravenous infusion is recommended to increase the duration of action of the drug. The solution for infusion is prepared on the basis of 50 or 500 ml of the following aqueous solutions: 0.9% sodium chloride solution, 10% aqueous levulose solution, 5% aqueous dextrose solution, Ringer acetate solution, Ringer lactate solution (Hartmann), colloidal dextran solution in 0 .9% sodium chloride solution or 5% dextrose solution. When diluting Artrosilene in small volume solutions (50 ml), the drug is administered intravenously as a bolus. In large volume solutions (500 ml), the infusion duration is at least 30 minutes.

Rectally 1 sup. 2–3 times a day. The maximum daily dose is 480 mg. In elderly patients, no more than 2 supp. should be used. per day.

Externally. A single dose of gel is 3–5 g (the volume of a large cherry), an aerosol is 1–2 g (the volume of a walnut). Depending on the size of the damaged area, the drug should be applied 2-3 times a day or as prescribed by the doctor, gently rubbing until completely absorbed. With iontophoresis, the drug is applied to the negative pole. The duration of treatment without consulting a doctor should not exceed 10 days.

special instructions

Capsules, solution for intravenous and intramuscular administration, suppositories

During treatment, it is necessary to monitor the peripheral blood picture and the functional state of the liver and kidneys.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

Taking ketoprofen can mask the signs of an infectious disease.

If renal or liver function is impaired, dose reduction and careful monitoring are necessary.

The use of ketoprofen by patients suffering from bronchial asthma can lead to an attack of bronchial asthma.

Women planning pregnancy should refrain from using the drug, because the likelihood of egg implantation may decrease.

Impact on the ability to drive vehicles and control machinery - during the period of use of the drug, you should refrain from potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

Gel, aerosol

The drug should be applied only to intact skin. Avoid contact with eyes and mucous membranes. To avoid hypersensitivity and photosensitivity, it is recommended to avoid exposure of the skin to sunlight during the course of treatment.